SLE | Control | |
---|---|---|
N | 22 | 20 |
Sex, female, n (%) | 20 (91%) | 18 (90%) |
Age, years | 51 (15) | 51 (12) |
Ethnicity, n (%) | ||
European | 13 (59%) | 17 (85%) |
Māori | 2 (9%) | 1 (5%) |
Pacific | 1 (5%) | 0 (0%) |
Asian | 6 (27%) | 1 (5%) |
Other | 0 (0%) | 1 (5) |
Body mass index, kg/m2 | 27.1 (7.0) | 26.3 (5.3) |
SLE disease duration, years | 14.3 (10.3) | - |
SLEDAI-2K | 12.0 (8.2) | - |
Medications, n (%) | ||
Hydroxychloroquine | 12 (55%) | |
Immunosuppressive | 10 (42%) | |
NSAID | 10 (45%) | |
Prednisone | 11 (50%) | |
Comorbidities and complications of disease, n (%) | ||
Raynaud’s syndrome | 9 (41%) | |
Lupus nephritis | 3 (14%) | |
Hypertension | 3 (14%) | |
Cardiovascular disease | 2 (9%) | |
Dyslipidaemia | 2 (9%) | |
Sjögren syndrome | 2 (9%) | |
Osteoporosis | 2 (9%) | |
Fibromyalgia | 1 (5%) | |
Depression | 2 (9%) |